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Excessive gut luminal iron has been shown to contribute to the initiation and 29 
progression of colorectal cancer. However, emerging evidence suggests that 30 
reduced iron intake and low systemic iron levels are also associated with the 31 
pathogenesis of colorectal cancer. This is of significance due to colorectal cancer 32 
patients often presenting with iron deficiency. Iron is necessary for appropriate 33 
immunological functions; hence, iron deficiency may hinder cancer 34 
immunosurveillance and potentially modify the tumour immune microenvironment. 35 
Both of which may assist in cancer development. This is supported by studies 36 
showing that colorectal cancer patients with iron deficiency have inferior outcomes 37 
and reduced response to therapy. Here, we provide an overview of the 38 
immunological consequences of iron deficiency and suggest ensuring adequate iron 39 
therapy to limit these outcomes. 40 
 41 
Introduction 42 
Colorectal cancer is the third most common cancer diagnosed globally and is the 43 
second leading cause of cancer mortality. Geographical variability exists within the 44 
prevalence of colorectal cancer, most often associated with a western lifestyle. 45 
Obesity, poor diet and a decline in physical activity are all known contributors to 46 
colorectal cancer development.1, 2 However, an emerging dietary contributor that has 47 
been linked to colorectal cancer is iron.  48 
 49 
Iron is a vital micronutrient that is central to many major biological functions, for 50 
instance, its role in the transport of oxygen within the iron-containing haemoglobin 51 




ability to transition through multiple oxidation states, within the cell the most 53 
commonly found being ferrous (Fe2+) and ferric (Fe3+) forms.4 In normal physiology 54 
iron is necessary for cellular proliferation. For instance, DNA synthesis requires the 55 
iron-dependent enzyme ribonucleotide reductase, which catalyses the rate-limiting 56 
step of DNA synthesis. Likewise, iron contributes to cell cycle progression, as it 57 
forms an essential part of the electron transport chain, providing energy production 58 
for cell cycling. As these processes which are necessary for cellular proliferation are 59 
dependent on iron, this allows the potential for iron to be utilised in pathological 60 
conditions such as cancer. Iron has been implicated in multiple tumour types, with 61 
the most notable being colorectal cancer.5 62 
 63 
Excessive intestinal iron within the gastrointestinal (GI) tract has been shown to have 64 
a role in increasing the risk of developing colorectal cancer.6 This is through its utility 65 
in cancer cell proliferation, contributing to oxidative stress-induced colonic damage, 66 
as well as amplifying oncogenic signalling.7, 8 In contrast, evidence to suggest a role 67 
for iron deficit in the pathogenesis of colorectal cancer is less well defined. This is of 68 
particular focus for investigation, due to iron deficiency being common in colorectal 69 
cancer patients. Iron deficiency can result in the clinical manifestation of anaemia 70 
within these patients, through limiting haematopoiesis.9, 10 As haematopoiesis 71 
produces all immune cells, along with iron being required for immune cell function, 72 
this leaves the potential for iron deficiency to cause an attenuated immune 73 
response.11, 12  If this is occurring in colorectal cancer patients this may lead to a 74 
reduced immunosurveillance response and altered tumour immune 75 




Hence, this review will address the consequences of iron deficiency on immune 77 
function and provide an insight into iron therapy in order to limit these outcomes. 78 
 79 
Iron Metabolism 80 
Before we can expand upon the role of iron in colorectal cancer, we first need to 81 
appreciate how iron is absorbed and regulated within the body. As iron is necessary 82 
for homeostasis its concentration is normally tightly controlled within the body.14 This 83 
occurs through being complexed to proteins that facilitate its absorption, 84 
transportation, storage and utilisation (Figure 1).4 Iron is present within the body by 85 
two means, through absorption or recycling.15 Dietary iron can be consumed in the 86 
form of haem iron (Fe2+) and non-haem iron (Fe3+).16 Initially, dietary iron is absorbed 87 
through the apical surface of enterocytes predominantly of the duodenum and upper 88 
jejunum, this is facilitated by both divalent metal transporter-1 (DMT-1) and haem 89 
carrier protein 1 (HCP-1).17, 18 Non-haem iron is reduced by duodenal cytochrome B 90 
(Dcytb) to Fe2+ before it can be transported by DMT-1 into the enterocyte. Likewise, 91 
HCP-1 absorbs haem iron before being internalised into the intestinal enterocytes. 92 
Once intracellular the enzyme haem oxygenase-1 (HO-1) releases iron from its 93 
haem complex.19 These mechanisms collectively contribute to the intracellular iron 94 
pool; iron then has one of two fates dependent on the body’s requirements for iron. If 95 
there is no iron requirement within the body, then the iron remains inert bound to the 96 
intracellular storage protein ferritin.18 This may be carried out by the chaperone 97 
protein poly binding protein 1 (PCBP1) which facili tates the loading of iron onto 98 
ferritin.20 In contrast, if iron is required by the body it will transverse the basolateral 99 
surface, by the efflux protein ferroportin (FPN), passing into the circulation .18 The 100 




system (MPS) which regulates iron recycling. MPS is central for iron homeostasis; 102 
specialized macrophages recycle iron through engulfment of senescent 103 
erythrocytes.15 These two mechanisms, recycling and absorption, regulate the input 104 
of iron into the circulation. Circulating iron is found associated with the plasma 105 
protein transferrin in order to maintain it in a redox inert state. Transferrin functions to 106 
deliver iron to all tissues, including the bone marrow for erythropoiesis, through 107 
binding to the cells surface transferrin receptor.17  108 
 109 
The absorption of iron is regulated by local iron levels, along with systemic factors. 110 
At the local level, iron concentration regulates the iron regulatory protein RNA 111 
binding activity, which in turn alters the levels of DMT-1 and FPN.18 Systemic signals 112 
regulating the body’s iron requirements are sensed by the liver, which in turn alters 113 
the expression of the iron regulatory hormone hepcidin. Hepcidin binds to the FPN 114 
leading to internalisation and degradation, which in turn limits the absorption of iron 115 
in the small intestine. Similarly, hepcidin regulates iron MPS recycling by causing 116 
sequestration of iron into macrophages.21 Factors influencing the liver’s production of 117 
hepcidin include the iron stores, erythropoiesis rate, hypoxia and inflammation  118 
(Figure 1). During inflammation, the cytokine IL-6 is necessary for the induction of 119 
hepcidin. This is seen during infection when pathogenic macromolecules such as 120 
lipopolysaccharides act on macrophages, such as the hepatic Kupffer cells, to 121 
induce production of IL-6 which in turn acts on hepatocytes to cause hepcidin mRNA 122 
production.22 123 
 124 




Only 10% of iron consumed in a typical diet is absorbed in the small intestine, this 126 
leaves the remnant iron residing within the GI tract.23 Excessive iron within the GI 127 
tract may contribute to increased proliferation and neoplastic conversion of colonic 128 
cells. Rodent studies have revealed increased dietary iron enhances proliferation of 129 
colonic crypt cells and amplifies colorectal tumour development.24, 25 This may be 130 
through irons utility in cellular proliferation, along with its ability to switch between 131 
oxidation states, which is tremendously toxic due to the production of reactive 132 
oxygen species from the Fenton ’s reaction.4 Reactive oxygen species increase 133 
oxidative stress within the GI tract that contributes to DNA damage, modification of 134 
proteins and lipid peroxification. Oxidative stress-induced damage to DNA may lead 135 
to genomic instability that can contribute to carcinogenesis.7 Similarly, excess iron-136 
induced oxidative stress can contribute to colonic inflammation.26 Chronic 137 
inflammation of the colon can contribute to colorectal cancer through the production 138 
of growth factors and cytokines that can support tumour growth, disrupt 139 
differentiation and promote cancer cell survival.27, 28  140 
 141 
The mechanisms linking excessive iron and colorectal cancer are further supported 142 
through the tumour suppressor gene adenomatous polyposis coli (APC). APC is 143 
recurrently mutated in sporadic and hereditary colorectal cancer.29 In vitro studies 144 
have shown that excessive iron in a background of APC mutation leads to an 145 
increase in signalling through the major oncogenic signalling pathway, Wnt.8 146 
Iron/APC-driven colorectal carcinogenesis has also been supported through an APC-147 
deficient murine model, where luminal iron depletion resulted in a reduction in 148 
tumour development, whereas, an increase in luminal iron promoted 149 




cancer, through increasing oxidative stress, inducing carcinogens and amplifying 151 
oncogenic signalling. 152 
 153 
The association between high iron and the risk of colorectal cancer has been well 154 
established. However, a study by Bird et al31 assessed 965 men and women aged 155 
50-75 to determine iron intake as a risk for development of adenomatous polyps, a 156 
precursor lesion to colorectal cancer. They found a U-shaped association between 157 
iron intake and colorectal polyps, showing that individuals that consume high iron 158 
(>27.3 mg/day) as well as low iron (<11.6 mg/day) had increased risk, compared to 159 
those consuming an adequate amount of iron (11.6-13.6 mg/day).31 This suggests 160 
that a deficit of iron could equally contribute to the pathogenesis of colorectal cancer 161 
as high iron does. A similar study by Cross et al32 supports this, showing an inverse 162 
association between serum iron levels and the risk of colon cancer.32 This may 163 
indicate that the level of iron within the blood may be contributing to cancer 164 
development when in shortage, in a similar way that excessive iron within the gut 165 
lumen contributes to tumour formation. The mechanism supporting iron deficiency 166 
and colorectal cancer development is not fully understood. However, it may involve 167 
cellular functions requirement for iron, which when deficient may hinder immune cells 168 
ability to protect against cancer.13  169 
 170 
Dietary Iron and Colorectal Cancer  171 
Many dietary components, frequently associated with iron, have been shown to 172 
contribute to or have protective roles against colorectal cancer. For instance, 173 
phytates are anti-nutrients that form complexes with dietary minerals including iron, 174 
leading to a reduction in bioavailability.33 Phytates are inhibitors of iron-induced 175 
8 
production of hydroxyl radicals, a potent oxidant that can contribute to cancer 176 
development.34 Likewise, vitamin C has been suggested to have a protective role 177 
against cancer through regulating iron. Vitamin C chelates iron, leading to greatly 178 
enhanced absorption of iron from the diet.35, 36 Vitamin C limits free radical damage 179 
through the quenching of reactive oxygen species and has been shown to modulate 180 
cancer cell survival.37, 38 This has been supported in a large population study 181 
showing that dietary intake of vitamin C is associated with a lower risk of colorectal 182 
cancer.39  183 
184 
Dietary iron is present in two forms, haem iron from animal sources such as red 185 
meat and non-haem iron from seeds, nuts, grains and dark green leafy vegetables.40,186 
41 Red meat including beef and lamb is characterised by a high myoglobin content 187 
which consists of increased levels of haem iron relative to white meat such as 188 
chicken.42 Dietary components of meat have been shown to contribute to colorectal 189 
cancer, for instance, N-nitroso compounds are mutagenic and are potent 190 
carcinogens.43, 44 Likewise, haem iron has also been shown to contribute to 191 
colorectal cancer via the Fenton’s reaction. Hydroxyl radicals produced by the 192 
Fenton’s reaction can alter DNA leading to oxidative base damage.45 Furthermore, 193 
haem iron has been shown to contribute cancer through inducing colonic 194 
hyperproliferation through modulation of the intestinal microbiota and inducing 195 
mutations through DNA adducts.46, 47 Haem iron also leads to the raised formation of 196 
lipid peroxyl radicals, such as malondialdehyde and 4-hydroxynonenal, which are 197 
potent carcinogens.3 This provides a strong association between haem iron and 198 
colorectal cancer, however, no evidence is available to link a mechanism of non -199 





This is supported in a study by Luo et al48 which assessed the different forms of iron 202 
and their association with colorectal cancer. They determined that haem iron was 203 
positively associated with colorectal cancer, whereas, non-haem iron showed no 204 
positive association. Supporting the role of excessive dietary haem iron, but not non-205 
haem iron, in the pathogenesis of colorectal cancer. Interestingly, along with 206 
excessive dietary haem iron, this study also determined that a lower intake of non-207 
haem iron was also associated with colorectal cancer.48 This supports previous 208 
studies by Bird et al31 and Cross et al32 showing that low iron is associated with 209 
cancer risk, however, this study expands upon this suggesting a reduction of non-210 
haem iron is responsible. 211 
 212 
Iron Deficiency Anaemia  213 
Colorectal cancer is commonly associated with the development of iron deficiency, 214 
which is prevalent in approximately 60% of colorectal cancer patients. Iron deficiency 215 
can then lead to the clinical manifestation of iron deficiency anaemia (IDA).9 216 
Causative mechanisms of colorectal cancer-associated IDA comprises chronic 217 
tumour-induced blood loss, reduced luminal absorption of iron and impairment of iron 218 
homeostasis prompted by chronic inflammatory disease.49 IDA induced through 219 
chronic GI bleeding results in a depletion of iron stores which leads to absolute iron 220 
deficiency (AID). Whereas, reduced uptake of iron, along with sequestration to the 221 
MPS, causes a decline in biologically available iron resulting in functional iron 222 
deficiency (FID).50 The clinical relevance of the distinction between AID and FID 223 




therapy irrespective of actual haemoglobin levels, whereas, in FID iron therapy is 225 
only recommended if anaemia induced symptoms occur.49  226 
 227 
Haematopoiesis is sensitive to iron deficiency, leading to the manifestation of 228 
anaemia in iron-deficient colorectal cancer patients.10, 49, 51 Haematopoiesis produces 229 
erythrocytes as well as immune cells such as T-cells, macrophages, dendritic cells 230 
and natural killer cells. Hence, this suggests that the effects of iron deficiency may 231 
not be restricted to the erythroid lineage and may influence the development and 232 
function of immune cells.11, 51 With iron deficiency being so prevalent within colorectal 233 
cancer, this review will address the implication of iron deficiency anaemia on immune 234 
function and how this may contribute to the pathogenesis of colorectal cancer. 235 
  236 
Iron Deficiency, Immune system and Infection 237 
Depletion of biologically available iron within the body due to iron deficiency results 238 
in the clinical manifestation of anaemia. However, iron is essential for all cells to 239 
function.52 Iron is critical in maintaining the immune system through regulating 240 
growth and differentiation of immune cells.12 Additionally, iron is essential for 241 
components of peroxide and nitrous oxide generating enzymes required for 242 
adequate enzymatic functionality of immune cells.53 Therefore, iron deficiency results 243 
in impaired cellular immunity, notably leading to defective T-cell maturation54, halting 244 
of macrophage differentiation55 and impaired natural killer cells activity.56 The 245 
association between iron deficiency and impairment of immune function has been 246 
confirmed, as patients with IDA have increased morbidity from infectious disease.57 247 
 248 




The immune system is essential to prevent infection; however, it is also required to 250 
detect and eliminate potentially transformed cells before they manifest into a 251 
malignancy. Transformed cells begin to express foreign antigen that can be 252 
recognised by the immune system. Immune cells act to survey the body for these 253 
cancerous or precancerous cells and eliminate them in a process called 254 
immunosurveillance.58 Hence, in order for cancer cells to survive they need to evade 255 
immune destruction, which is a hallmark of cancer.59 Iron plays an essential role in 256 
immunosurveillance, through its utilisation in growth and differentiation of immune 257 
cells, as well as influencing cell-mediated immune response and cytokines 258 
activities.60 Therefore, iron deficiency provides the potential for a suppressed 259 
immunosurveillance response, which may contribute to tumour immune cell evasion 260 
and inadequate tumour cell destruction.61 How iron deficiency alters the major 261 
immune cells and cytokines involved in the immune surveillance response are 262 
discussed below. 263 
 264 
Dendritic Cells 265 
Dendritic cells are the most potent antigen-presenting cells that bridge the innate and 266 
adaptive immune systems and are required for activation of the antitumor T cells.62 267 
Iron plays a key role in the differentiation of dendritic cells through supporting the 268 
induction of the cyclin-dependent kinase inhibitor p21. Iron deprivation of dendritic 269 
cells results in an undifferentiated phenotype, with absent or blunted dendritic 270 
processes, that are unable to stimulate T cells. Depletion of iron leads to an increase 271 
in the cell surface localisation of transferrin receptors on dendritic cells, suggesting 272 




reduction in the activation of antitumor T cell response, through impaired dendritic 274 
cell function.63 275 
T-Cells 276 
T cells are critical to immunosurveillance through their various subtypes. Cytotoxic T 277 
cells are major effector cells in the immune response against cancer, through their T 278 
cell receptors ability to recognise tumour associated antigens on cancer cells.64 279 
Cytotoxic T cells then induce apoptosis of tumour cells through perforin and 280 
granzyme mediated cell lysis.65 Helper T cells act to support this mechanism through 281 
aiding dendritic cells in activating cytotoxic T cells, along with produ cing cytokines 282 
such as IL-2 and IFN-gamma to recruit and activate T cells and natural killer cells.66 283 
However, in IDA these mechanisms are suboptimal. 284 
 285 
Iron deficiency has been shown to cause a reduction of circulating T cells through a 286 
limitation of T cell proliferation.67 Similarly, iron deficiency also leads to a reduction in 287 
T cell motility through inhibiting protein kinase C.13 The overlying mechanism that 288 
results in these iron deficiency-induced T cell dysfunction may be through increased 289 
oxidative stress, due to an increase in oxidant levels along with a decrease in 290 
antioxidant enzymatic activity associated with iron deficit. This increase in oxidative 291 
stress caused by IDA induces DNA damage in lymphocytes; this was confirmed in a 292 
study by Aslan et al68 which showed that lymphocyte DNA damage was significantly 293 
increased in patients with IDA. Lymphocyte DNA damage may result in a defective T 294 
cell population, contributing to an impaired immune response.68, 69 T cells act as the 295 
key cells in immunosurveillance, which if repressed create a favourable condition for 296 





Natural Killer Cells 299 
Natural killer cells are specialised cytotoxic cells that play a pivotal role in 300 
immunosurveillance through perforin and granzyme mediated tumour cell 301 
destruction.70 Stress associated ligands are present on tumour cells, such as HSP70 302 
and MICA/B. These stimulate natural killer cells through activating receptors, NKG2D 303 
and NKp46, allowing natural killer cells to detect cancer cells. However, IDA can lead 304 
to an impairment of natural killer cells antitumor activity through the induction of 305 
hypoxia. Hypoxia leads to a downregulation of natural killer cell -activating receptors, 306 
NKG2D and NKp46, as well as decreasing the presence of stress associated ligands 307 
HSP70 and MICA/B on cancer cells.71, 72 Hypoxia also leads to a degradation of 308 
natural killer cell-derived granzyme B that is required for the elimination of cancerous 309 
cells.73 Hence, IDA patients may have reduced immunosurveillance abilities of 310 
natural killer cells, which have the potential to allow evasion of cancer cell 311 
destruction by the immune system.13 312 
 313 
IL-2 314 
IL-2 is an essential cytokine regulating immunosurveillance. IL-2 is produced by 315 
lymphocytes and is critical for the proliferation of naïve T cells and their 316 
differentiation into antitumoral effector T cells.74 Release of IL-2 is also vital in the 317 
communication between T cells and natural killer cells.75 Furthermore, IL-2 is 318 
required to stimulate the growth and activity of natural killer cells, in order for them to 319 
exert their antitumor responses. Therefore, IL-2 plays a pivotal role in regulating the 320 
immunosurveillance cellular response to cancer. However, in vitro studies have 321 
assessed the implications of iron deficiency on immune cell cytokine production. 322 




This may lead to a reduced antitumoral immune response in patients with IDA, as IL-324 
2 may be required by the immune system to control cancer.74 This has been 325 
supported in colorectal cancer mouse models, where increased IL-2 expression was 326 
associated with inhibited tumour formation and growth . 76 Therefore, a reduction in 327 
IL-2 production associated with iron deficiency creates a dampened immunological 328 
environment that may be more passive to cancer development. 329 
 330 
IFN-gamma 331 
IFN-gamma is a cytokine released by T helper cells, which acts to aid the 332 
immunosurveillance antitumor response through helping to recruit and activate 333 
natural killer cells.77, 78 Hence, IFN-gamma acting on natural killer cells acts to limit 334 
tumour growth and metastasis.79 However, iron deficiency leads to a reduction in 335 
IFN-gamma secretion.80 IFN-gamma is a pleiotropic cytokine that has anti-336 
proliferative, pro-apoptotic and general antitumor effects. Hence a decrease in IFN-337 
gamma in IDA may lead to a hindering of natural killer cell function and creating a 338 
protumorigenic cytokine environment.81 Supporting evidence implicates a decline in 339 
IFN-gamma in the pathogenesis of colorectal cancer, as a decline in IFN-gamma 340 
contributes to the proliferation of APC mutant cells through altering EGF and Wnt-341 
mediated signalling.82 Further supportive evidence has shown that colorectal cancer 342 
patients with lower levels of IFN-gamma, present with significantly worse survival.83 343 
This data suggests that IFN-gamma has a protective role against colorectal cancer, 344 
which is dampened through iron deficiency. 345 
Iron Deficiency and Tumour Microenvironment 346 
IDA may alter immune cell function leading to an insufficient immunosurveillance 347 




iron deficiency may also alter immune cells within the tumour microenvironment, 349 
causing them to exert a protumourgenic response.  350 
Macrophages 351 
Red blood cell haem degradation contributes to iron recycling in the MPS. Spleen 352 
and liver macrophages are responsible for this by converting haem to ferrous iron 353 
through the expression of high levels of the enzyme HO-1. Tumour-associated 354 
macrophages (TAMs) are present in the tumour microenvironment and dependent 355 
on their polarization phenotype contribute to tumour development or regression , in 356 
part through regulating iron availability for use in cancer cell proliferation. M1 357 
classically activated macrophages are pro-inflammatory, express high intracellular 358 
levels of ferritin that sequesters iron and promote tumour regression. Whereas, M2 359 
macrophages favour tumour growth in part through upregulation of HO-360 
1 mediated iron generation and increased iron export to the tumour 361 
microenvironment. HO-1 is expressed in residential macrophages and recruited 362 
monocytes within the tumour stroma, hence iron recycling in the tumour 363 
microenvironment is dependent heavily on the TAM activity.84, 85 In vitro studies have 364 
shown that depending on TAM polarisation there are different tumour responses, 365 
through HO-1-induced iron production and export to the tumour microenvironment. 366 
Conditioned media from M2 macrophages lead to more effective stimulation of 367 
cancer cell proliferation than that of M1 macrophages. This was dampened by iron 368 
chelation, suggesting that increased iron export to the tumour microenvironment by 369 
M2 macrophages is responsible for enhanced cellular proliferation.86 370 
 371 
Therefore, in individuals with IDA, there may be the potential for there to be a 372 




releasing M2 macrophages. This has been supported in vitro were bone marrow-374 
derived macrophages treated with iron showed an increase in M1 polarisation 375 
phenotype, while decreasing M2 phenotype.87 Hence, in individuals with iron 376 
deficiency there may be a reduction in M1 polarisation and a loss of inhibition of M2 377 
polarisation. Similarly, research into the effects of iron therapy on immune function 378 
against cancer has revealed that iron-loaded TAMs induced through injection of iron 379 
oxide nanoparticle lead to reduced tumour size within in vivo models. This occurs 380 
through the iron treatment leading to repolarization of TAMs to exert an antitumor 381 
effect.88 382 
 383 
Previously discussed is the role of IFN-gamma deficit induced by iron deficiency 384 
driving colorectal cancer. This is further supported in  a study using APC deficient 385 
multiple intestinal neoplasia mice that lack IFN-gamma signalling. This lack of IFN-386 
gamma signalling led to an accumulation of TAMs which were more prone to M2 387 
polarisation.81 388 
Regulatory T-cells 389 
Regulatory T-cells (T-Regs) have an indispensable function in peripheral tolerance, 390 
preventing detrimental immunopathological responses against self and unharmful 391 
foreign antigens.89 The risk of developing cancer increases as a result of unregulated 392 
immunological responses, as seen in patients with inflammatory bowel disease wh o 393 
have increased risk of developing colorectal cancer. This occurs through multiple 394 
mechanisms, for instance, persistent activation of the immune system in chronic 395 
inflammation can contribute tumour promoting growth factors and cytokines. Anti-396 
inflammatory CD4+ T-Regs act to reinstate immune homeostasis during chronic 397 




deficiency on T-Regs. Iron chelation resulted in impaired T-Reg activation and 399 
proliferation.92 This suggests that iron deficiency may lead to the loss of the 400 
immunosuppressive effects of T-Regs in the tumour microenvironment, which may 401 
contribute to chronic inflammation which is associated with colorectal cancer. 402 
 403 
Implications of Iron Deficiency on Colorectal Cancer   404 
The consequence of iron deficiency anaemia on the immune system’s ability to 405 
prevent cancer 406 
A 2015 population study conducted by Hung et al93 evaluated the risk of cancer in 407 
patients with IDA. They determined that there was a significantly increased risk of 408 
developing cancer in patients with IDA, irrespective of age or gender.93  A similar 409 
study by Ioannou et al94 assessed explicitly GI malignancies, with their findings 410 
revealing GI tumours to be more prevalent in men and postmenopausal women with 411 
IDA compared to those with normal iron levels. However, this was not seen in 412 
premenopausal women.94 These studies suggest an association between IDA and 413 
the development of cancer. Which may be due to an impairment of immune function, 414 
allowing tumour cell evasion through diminished immunosurveillance or due to a 415 
switch to protumorigenic immune cell function within the tumour microenvironment. 416 
Further supporting this, in animal studies oral carcinogen lead to earlier cancer 417 
development in iron-deficient rats, compared to those with normal iron levels.95 418 
 419 
Iron deficiency anaemia exacerbates colorectal cancer  420 
Patients with IDA have been shown to have an increased risk of developing tumours. 421 
However, IDA is commonly present in patients with predating colorectal cancer. 422 




patients’ pre-existing cancer. This may be through limiting the immune system’s 424 
ability to limit tumour growth, hindering responses to therapy and restricting the 425 
immune system's response to circulating tumour cells which may develop into distant 426 
metastasis.96 This has been assessed in clinical studies which showed that 427 
colorectal cancer patients with IDA have inferior outcomes than those without IDA, 428 
presenting with worse tumour staging and lower disease-free survival.97 429 
 430 
Iron deficiency anaemia and response to therapy 431 
IDA may also lead to a reduced response to therapies, such as surgery and 432 
chemotherapy. Preoperative anaemia in colorectal cancer patients, usually induced 433 
through iron deficiency, leads to a decreased survival following surgery.98 This may 434 
be due to the immune’s systems requirements to prevent dissemination of cancer 435 
cells following surgery. IDA may impair immune function allowing ci rculating tumour 436 
cells induced through surgery to be undetected and to form metastasis. Similar 437 
evidence has supported the fact that anaemia leads to inferior patient outcomes 438 
following treatment, a study by An et al99 showed that patients with preoperative 439 
anaemia treated with adjuvant FOLFOX chemotherapy presented with a worse 440 
prognosis, than those without anaemia.99 441 
 442 
Iron Therapy 443 
Oral iron therapy is the current standard treatment for IDA.100 However, this has 444 
been shown to increase the concentration of luminal iron within the GI tract, which 445 
increases oxidative stress and inflammation that may contribute to the progression of 446 
colorectal cancer.101 In contrast, studies assessing preoperative IDA in colorectal 447 




and treats iron deficiency more effectively than oral iron, without contributing to gut 449 
iron concentration.102 This is further supported in patients with FID that have reduced 450 
luminal iron absorption, therefore oral iron is poorly absorbed in the duodenum of 451 
these patients and can contribute to gut iron concentration. Whereas, intravenous 452 
iron is more effective at treating iron deficiency in FID patients.49, 50 453 
 454 
Oral iron supplementation has been shown to have a variety of GI side-effects 455 
including abdominal pain, dyspepsia, constipation and diarrhoea. Leading to non-456 
compliance as a result of these side-effects. In contrast, intravenous iron has been 457 
shown to be better tolerated, with fewer GI side-effects.103  Furthermore, many 458 
studies have been conducted to support the efficacy and safety of intravenous iron 459 
therapy preoperatively in colorectal patients with IDA. A 2020 study by Kam et al104, 460 
showed that colorectal cancer patients with IDA who received intravenous iron 461 
therapy had significantly increased haemoglobin levels prior to surgery, as well as 462 
requiring less red blood cell transfusions, compared to patients not treated with 463 
intravenous iron. This study also supported the safety of intravenous iron, stating 464 
that they observed no iron-related adverse events following treatment.104  465 
 466 
This suggests that intravenous iron may provide a more adequate therapy to treat 467 
IDA in colorectal cancer patients, compared to oral iron supplementation. 468 
Intravenous iron may be a more beneficial therapy by providing optimum repletion of 469 






Multiple studies have shown that excessive gut luminal iron contributes to colorectal 473 
carcinogenesis, through increasing oxidative stress, contributing to inflammation  and 474 
providing iron for cancer cell proliferation. However, the implication of iron deficiency 475 
on colorectal cancer has not been fully assessed. This is of prominent need for 476 
investigation due to colorectal cancer patients often presenting with IDA. Iron is 477 
necessary for correct immunological function. Hence, iron deficiency may result in a 478 
dampened immunosurveillance response, most notably leading to impairments of 479 
dendritic cells, T-cells and natural killer cells. Along with this, iron deficiency can 480 
modify macrophage polarization and alter T-reg populations, promoting a 481 
procarcinogenic tumour immune microenvironment. Collectively these mechanisms 482 
may link why patients with IDA have significantly increased risk of developing 483 
cancer, have worse colorectal cancer tumour staging, reduced disease-free survival, 484 
and reduced response to therapy (Figure 2). Therefore, in order to limits these 485 
outcomes, adequate iron therapy is necessary. Oral iron is typically given to 486 
colorectal cancer patients with IDA; however, this increases gut luminal iron 487 
concentration and does not provide optimum replenishment of iron stores. Studies 488 
assessing iron therapy in colorectal cancer patients with IDA have shown that 489 
intravenous iron was more effective at replenish ing iron stores and treating iron 490 
deficiency anaemia than oral iron supplements. This suggests that intravenous iron 491 
therapy may be more beneficial in supporting cancer immunosurveillance and 492 
limiting pro-tumorigenic microenvironment, without the oncogenic consequences of 493 
increasing gut luminal iron. 494 
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 Figure 1: Schematic representation of systemic iron regulation. 766 
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Figure 2: Summary of how colorectal cancer causes iron deficiency anaemia 768 
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